Pey-Jen Yu

Northwell Health

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

196

PubMed author-name match

Trials

Studies that name Pey-Jen Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:54 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT07032792 · Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
Northwell Health · recruiting · Cardiac Disease, Surgery, Bleeding · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 04:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:54 UTC. The ranking covers the 200 most relevant of 196 PubMed records, and a shared surname and initials can bring in a namesake. All 196 on PubMed

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol · 2018
463 citations
RCR 14.6
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Lancet Oncol · 2021
384 citations
RCR 22.8
Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial.
Ann Surg · 2005
363 citations
RCR 11.2
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Ann Oncol · 2017
295 citations
RCR 8.5
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
J Clin Oncol · 2021
228 citations
RCR 11.8
Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial.
JAMA Oncol · 2020
191 citations
RCR 12.1
Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial.
Diabetes Res Clin Pract · 2013
166 citations
RCR 5.9
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Circ Cardiovasc Interv · 2016
138 citations
RCR 4.3
A comparative study of patient controlled epidural analgesia (PCEA) and continuous infusion epidural analgesia (CIEA) during labour.
Can J Anaesth · 1988
133 citations
RCR 11.1
Low-dose creatine combined with protein during resistance training in older men.
Med Sci Sports Exerc · 2008
120 citations
RCR 4.3